Successful nilotinib therapy in a CML affected patient with A380T, P407S and V468A mutations, and a previous suboptimal cytogenetic response to imatinib

Successful nilotinib therapy in a CML affected patient with A380T, P407S and V468A mutations, and a previous suboptimal cytogenetic response to imatinib

Imatinib mesylate (IM) has shown unprecedented effectiveness in the treatment of Chronic Myeloid Leukemia (CML) patients (pts) in the chronic phase of the disease. However, some pts fail to respond or lose their initial response to IM. The European LeukemiaNet (ELN) published recommendations designe...

Full description

Bibliographic Details
Main Authors: Fabio Stagno, Alessandra Cupri, Stefania Stella, Michele Massimino, Silvia Rita Vitale, Paolo Vigneri
Format: Article
Language:English
Published: SEEd 2015-10-01
Series:Clinical Management Issues
Subjects:
Nilotinib
Chronic myeloid leukemia
Therapy
Tyrosine kinase inhibitors
Online Access:https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1097

Internet

https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1097

Similar Items